Predictive models for transient protein expression in tobacco (Nicotiana tabacum L.) can optimize process time, yield, and downstream costs
- 17 April 2012
- journal article
- research article
- Published by Wiley in Biotechnology & Bioengineering
- Vol. 109 (10), 2575-2588
- https://doi.org/10.1002/bit.24523
Abstract
The transient expression of recombinant biopharmaceutical proteins in plants can suffer inter-batch variation, which is considered a major drawback under the strict regulatory demands imposed by current good manufacturing practice (cGMP). However, we have achieved transient expression of the monoclonal antibody 2G12 and the fluorescent marker protein DsRed in tobacco leaves with ∼15% intra-batch coefficients of variation, which is within the range reported for transgenic plants. We developed models for the transient expression of both proteins that predicted quantitative expression levels based on five parameters: The OD600nm of Agrobacterium tumefaciens (from 0.13 to 2.00), post-inoculation incubation temperature (15–30°C), plant age (harvest at 40 or 47 days after seeding), leaf age, and position within the leaf. The expression models were combined with a model of plant biomass distribution and extraction, generating a yield model for each target protein that could predict the amount of protein in specific leaf parts, individual leaves, groups of leaves, and whole plants. When the yield model was combined with a cost function for the production process, we were able to perform calculations to optimize process time, yield, or downstream costs. We illustrate this procedure by transferring the cost function from a production process using transgenic plants to a hypothetical process for the transient expression of 2G12. Our models allow the economic evaluation of new plant-based production processes and provide greater insight into the parameters that affect transient protein expression in plants. Biotechnol. Bioeng. 2012; 109: 2575–2588.Keywords
This publication has 27 references indexed in Scilit:
- GMP issues for recombinant plant-derived pharmaceutical proteinsBiotechnology Advances, 2012
- Quantitative plant proteomicsProteomics, 2011
- Defining process design space for monoclonal antibody cell cultureBiotechnology & Bioengineering, 2010
- Tobacco, a highly efficient green bioreactor for production of therapeutic proteinsBiotechnology Advances, 2010
- Optimisation of contained Nicotiana tabacum cultivation for the production of recombinant protein pharmaceuticalsTransgenic Research, 2009
- A model of Agrobacterium tumefaciens vacuum infiltration into harvested leaf tissue and subsequent in planta transgene transient expressionBiotechnology & Bioengineering, 2008
- Scale‐Up of Agrobacterium‐Mediated Transient Protein Expression in Bioreactor‐Grown Nicotiana glutinosa Plant Cell Suspension CultureBiotechnology Progress, 2008
- Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localizationJournal of General Virology, 2007
- Pharma-Planta: road testing the developing regulatory guidelines for plant-made pharmaceuticalsTransgenic Research, 2007
- Rapid Flow Cytometric Analysis of the Cell Cycle in Intact Plant TissuesScience, 1983